Where Ancient Wisdom Meets Modern Science
Pioneering Research That’s Rewriting the Future of Healing
At The Iboga Institute, we are committed to rigorous scientific inquiry and evidence-based practice. Our research initiatives bridge traditional knowledge with modern neuroscience, contributing to the growing body of literature on ibogaine’s therapeutic potential.
Our Research Mission
The Iboga Institute exists at the intersection of ancestral wisdom and cutting-edge science. We recognize that iboga has been used ceremonially for generations, and we honor this legacy by pursuing research that:
Validates therapeutic applications through peer-reviewed studies
Respects indigenous knowledge and ensures ethical access
Enhances safety protocols and clinical best practices
Contributes to global scientific understanding
Explores novel treatment areas and client populations
Groundbreaking Research Shaping the Field
The Iboga Institute draws upon and contributes to a rapidly expanding body of peer-reviewed scientific literature. Below are landmark studies that inform our evidence-based approach to ibogaine therapy.
Breakthrough Studies from Leading Universities
Stanford University
Magnesium-Ibogaine Therapy in Veterans with Traumatic Brain Injuries, Nature Medicine, 2024
This landmark clinical trial evaluated 30 retired Navy SEALs with traumatic brain injury who demonstrated major improvements across a variety of psychometric symptoms, including disability, post-traumatic stress, depression and anxiety. The study helped spark a major upsurge in ibogaine research and even state-level funding initiatives in the U.S.
Johns Hopkins University
Psychedelics Reopen Critical Periods for Social Learning
Nature, 2023
Johns Hopkins researchers discovered that psychedelic drugs, including ibogaine, can reopen critical periods in the brain when mammals are more sensitive to learning from their environment. For ibogaine specifically, the critical period remained open for four weeks following a single dose—the longest duration among all psychedelics tested.
University of California, Davis
Total Synthesis of Ibogaine Opens New Research Pathways
Nature Chemistry, 2025
UC Davis researchers achieved the total synthesis of ibogaine and related compounds from inexpensive, widely available chemicals. This breakthrough enables efficient production of ibogaine analogues for research, potentially leading to safer, more targeted treatments.
Yale & UCSF Collaboration
Safer Ibogaine-Inspired Compounds for Addiction
Cell, 2023
Researchers virtually screened 200 million molecular structures to identify compounds that mimic ibogaine’s therapeutic effects without its side effects. The study demonstrated that these compounds effectively treated symptoms of depression, anxiety, and opioid withdrawal in animal models.
Pioneering Research on Neurological Applications
Ambio Life Sciences & Canadian Researchers, 2025
Frontiers in Immunology: Ibogaine Treatment for Multiple Sclerosis
This groundbreaking case report documented two MS clients who showed remarkable neuroimaging changes and clinical improvements following ibogaine treatment. One client demonstrated a 71% reduction in the volume of white matter lesions post-treatment.
Findings:
- Substantial lesion shrinkage suggesting remyelination
- Decreased inflammation markers in brain tissue
- Improvements in motor function and cognitive processing
- Changes in cortical and subcortical brain regions
University of the Witwatersrand & University of Cape Town, 2024
Frontiers in Neuroscience: Ibogaine Upregulates Myelination Markers
Preclinical research demonstrated that ibogaine upregulates genes and proteins involved in remyelination, highlighting an important mechanism for brain injury repair and treatment of substance use disorders. This research has implications for multiple sclerosis, stroke, and other myelin-associated diseases.
Clinical Outcome Studies
Johns Hopkins Medicine
Subjective Effectiveness for Opioid Use Disorder
Journal of Psychedelic Studies, 2018
This study surveyed 88 clients who received ibogaine treatment, providing valuable long-term outcome data. Most participants (80%) reported that ibogaine eliminated or drastically reduced withdrawal symptoms, with 30% achieving complete abstinence from opioids.
Long-Term Outcomes:
- 50% reported ibogaine reduced opioid craving, with 25% reporting reduction lasting at least 3 months
- Nearly half of abstainers maintained abstinence for one year
- Strong spiritual experiences correlated with better outcomes
University of Otago
12-Month Follow-Up Observational Study Journal of Psychopharmacology, 2017
This New Zealand study followed 14 clients after ibogaine treatment for opioid dependence over 12 months. The legal status of ibogaine in New Zealand provided a unique opportunity to evaluate durability of treatment outcomes in a medically supervised setting.
University of Basel
Systematic Literature Review of Clinical Trials Journal of Substance Abuse Treatment, 2022
This comprehensive systematic review analyzed 24 studies involving 705 participants. Data suggest ibogaine is an effective therapeutic intervention for substance use disorders, reducing withdrawal symptoms and craving, while also showing beneficial impact on depressive and trauma-related symptoms.
Conclusions:
- Rapid-onset therapy offers novel treatment opportunities
- Rigorous study designs within medical settings necessary for safe application
- Need for continued research on safety protocols
State & Federal Research Initiatives
The therapeutic potential of ibogaine has captured the attention of government agencies and state legislatures, leading to unprecedented funding for research:
Texas Ibogaine Research
Initiative (2025)
The state of Texas allocated $50 million to fund clinical research on ibogaine, aiming to develop an FDA-approved treatment for opioid use disorder and other conditions. This initiative established a consortium of universities, hospitals, and drug developers, positioning Texas as a leading center for psychedelic medicine research.
Kentucky Opioid Abatement
Advisory Commission
Kentucky considered allocating $42 million from opioid lawsuit settlements to study ibogaine therapy, marking the first time a U.S. state explored funding research into this approach. The move underscores the urgent need to expand treatment options for the opioid epidemic.
National Institutes of Health (NIH)
After a decades-long hiatus, the NIH has begun awarding grants for psychedelic research, including studies on ibogaine analogues and related compounds. This represents the first significant federal funding for psychedelic therapeutic research in over half a century.
National Institute on Drug Abuse (NIDA)
NIDA is actively working with pharmaceutical startups to investigate how ibogaine and its analogues might be used to treat drug dependency, focusing on developing safer, non-hallucinogenic versions that retain therapeutic efficacy.
The Science Behind the Healing
From addiction recovery to neurological regeneration, ibogaine research spans multiple therapeutic frontiers. Here’s how the scientific community is unlocking ibogaine’s potential across diverse medical applications—each backed by rigorous clinical evidence and groundbreaking discoveries.
Transparency You Can Trust
Our primary research focus examines ibogaine’s efficacy in treating various forms of addiction, including opioid dependence, alcohol use disorder, stimulant addiction, and polysubstance dependence.
Key Studies:
- Opioid withdrawal reduction and craving cessation
- Alcohol use disorder treatment outcomes
- Cocaine and methamphetamine addiction protocols
- Long-term abstinence and relapse prevention
Mental Health Applications
Emerging research demonstrates ibogaine’s potential for treating depression, anxiety, PTSD, and other mental health conditions, particularly in treatment-resistant cases.
Research Areas:
- Treatment-resistant depression protocols
- Complex trauma and PTSD recovery
- Anxiety disorders and panic conditions
- Integration with psychotherapy modalities
Neurological Conditions
Novel applications of ibogaine in neurological health represent a frontier in psychedelic medicine, with preliminary evidence suggesting neurorestorative properties.
Investigational Studies:
- Traumatic brain injury recovery
- Cognitive decline and memory disorders
- Chronic pain and neuropathy management
- Neurodegenerative condition exploration
Safety & Pharmacology
Understanding ibogaine’s pharmacokinetics, drug interactions, and safety profile remains essential to advancing responsible clinical use.
Research Focus:
- Cardiac safety protocols and risk mitigation
- Drug interaction profiles and contraindications
- Dosing optimization for different populations
- Novel co-therapy approaches
Clinical Guidelines & Protocols
Evidence-Based Treatment Standards
The Iboga Institute has contributed to the development of international clinical guidelines that establish best practices for ibogaine administration. Our protocols emphasize:
Pre-Treatment Assessment
- Comprehensive medical screening
- Cardiac evaluation (ECG, echo, troponin)
- Psychological readiness assessment
- edication review and tapering protocols
Treatment Environment
- 24/7 medical monitoring
- Advanced cardiac telemetry
- Experienced clinical staff ratios
- Integration support planning
Post-Treatment Care
- Structured aftercare programming
- Integration therapy sessions
- Ongoing medical follow-up
- Peer support connection











